SCiP™—A game-changing new treatment for cerebral palsy

Cerebral palsy is the most common movement disorder in pediatrics.

Now, after decades of scientific research, SpineX is proud to introduce, Spinal Cord Innovation in Pediatrics (SCiP™), a novel device proven to treat the root cause of CP through spinal cord neuromodulation.

Clear results

The effects of spinal cord neuromodulation on children with cerebral palsy are clear. See for yourself in this before-and-after demonstration of our SCiP™ device.

Patient testimonial

Witness the dramatic effects of our non-invasive technology (SCiP™) on a child living with spastic quadriplegic cerebral palsy and global developmental delays.

SCiP™ has been recognized by the FDA as a Breakthrough Device

A multi-center pivotal trial on children with cerebral palsy is anticipated to begin in H1 2024.

Bringing innovation to market

At SpineX, accessibility is key to our mission. We are pushing the boundaries of research to find the most effective solutions for patients with neurological conditions and, with our devices on the market, we will have the potential to impact millions of people around the world.

SCiP™ and SCONE™ are investigational devices and are limited by Federal (USA) law to investigational use only. The FDA has not reviewed the safety and efficacy for SCiP™ and SCONE™
To top